Deutsche Bank upgraded Agilon Health (AGL) to Buy from Hold with a price target of $49, up from $33. The firm cites the improving macro environment and “compelling” share valuation at current levels for the upgrade after Agilon upped its guidance. The company raised its full-year guidance reflecting the strong Q1 results and higher risk scores expectation for the year, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL: